Day One Biopharmaceuticals Inc
Day One Biopharmaceuticals — Q2 2023 Earnings Presentation
46 slides from Day One Biopharmaceuticals's earnings presentation, Aug 7, 2023
Slide 1: Targeted Therapies for People of All Ages
Day One Biopharmaceuticals Targeted Therapies for People of All Ages August 2023 Day One Biopharmaceuticals
Slide 2: Disclaimer
Disclaimer Day One Biopharmaceuticals This presentation and the accompanying oral commentary contain forward-looking statements that are based on our management’s beliefs and assumptions and on information currently available to our management. Forward-looking statements are inherently subject to ri
Slide 3: Cancer Drug Development For People Of All Ages
Cancer Drug Development For People Of All Ages Day One Biopharmaceuticals Growing Portfolio and Runway Beyond Clinical Milestones Tovorafenib (DAY101) Lead Program Mission That Creates Value Day One’s mission is to help children with cancer, from day one and every day after Develop medicines for gen
Slide 4: Our Pipeline
Our Pipeline Day One Biopharmaceuticals Product Candidate Indication Preclinical Phase 1 Phase 2 Phase 3 Recent & Anticipated Milestones Tovorafenib (DAY101) Type II Pan-RAF Inhibitor Relapsed pLGG Frontline pLGG RAF-altered solid tumors2 (monotherapy) Pimasertib MEK 1/2 Inhibitor MAPK-altered solid
Slide 5: Tovorafenib (DAY101) Type II RAF Inhibitor
Tovorafenib (DAY101) Type II RAF Inhibitor Day One Biopharmaceuticals
Slide 6: Pediatric Low-Grade Glioma: The Most Common Type Of Brain Tumor In Children
Pediatric Low-Grade Glioma (pLGG): The Most Common Type Of Brain Tumor In Children Day One Biopharmaceuticals PLGGs are chronic and relentless, with patients suffering profound tumor and treatment-associated morbidity that can impact their life trajectory over the long term6 A Serious and Life-Threa
Slide 7: Current Treatments Can Be Disruptive To Childhood
Day One Biopharmaceuticals Current Treatments Can Be Disruptive To Childhood and Can Have Significant Long-Term Consequences Rash Fever Vomiting Fatigue Anemia Nail infections Ophthalmologic toxicity Cardiac toxicity Significant recovery times Risks of complications Resection may be limited by locat
Slide 8: Tovorafenib Inhibits Both BRAF Fusions And BRAF V600 Mutations
Tovorafenib (DAY101) Inhibits Both BRAF Fusions And BRAF V600 Mutations Day One Biopharmaceuticals Source: 1. Sun Y et al., Neuro Oncol. 2017; 19: 774–85; 2. Sievart AJ et al., PNAS. 2013; 110:5957-62; 3. Karajannis MA et al., Neuro Oncol 2014;16(10):1408-16 Tovorafenib (DAY101) is an investigationa
Slide 9: The Current pLGG Treatment Paradigm
The Current pLGG Treatment Paradigm Reflects The Unrelenting Nature Of This Chronic Brain Tumor Day One Biopharmaceuticals Because many pLGGs undergo senescence when patients reach their 20s, the goal of therapy is to maximize tumor control while minimizing treatment-associated toxicities from surge
Slide 10: Pivotal Phase Trial Of Tovorafenib In Relapsed Or Progressive pLGG (FIREFLY-1)
Pivotal Phase 2 Trial Of Monotherapy Tovorafenib (DAY101) In Relapsed Or Progressive pLGG (FIREFLY-1) Day One Biopharmaceuticals Primary endpoint: ORR based on RANO-HGG1, assessed by blinded independent central review Secondary endpoints: ORR by RAPNO-LGG2 assessed by blinded independent central rev
Slide 11: FIREFLY-1 Baseline Patient Characteristics
FIREFLY-1 Baseline Patient Characteristics Day One Biopharmaceuticals Dec 22, 2022 data cutoff. *Includes tumors that were extending into multiple regions of the brain, leptomeningeal disease, and/or spinal disease. #Includes 6 patients with BRAF duplication and 2 with BRAF rearrangement per FISH (F
Slide 12: Tumor Response By RANO-HGG (n=69)
Tumor Response To Tovorafenib (DAY101) For All Patients With RANO-HGG Evaluable Lesions (n=69) Day One Biopharmaceuticals Response (IRC) RANO-HGG1 Evaluable n=69 ORR (cCR + cPR + uPR), n (%) 46 (67%)* Clinical benefit rate, n (%) cCR, cPR/uPR, or SD cCR, cPR/uPR, or SD for 12 mo+ 64 (93%) 49 (71%) B
Slide 13: Tumor Response By RAPNO-LGG (n=69)
Tumor Response To Tovorafenib (DAY101) For All Patients With RAPNO-LGG Evaluable Lesions (n=69*) Day One Biopharmaceuticals Response (IRC) RAPNO-LGG1 Evaluable n=69 ORR (cCR + cPR/uPR + cMR/uMR), n (%) 35 (51%) Clinical benefit rate, n (%) cCR, cPR/uPR, cMR/uMR, or SD cCR, cPR/uPR, cMR/uMR, or SD fo
Slide 14: Tumor Response By RANO-LGG (n=76)
Tumor Response To Tovorafenib (DAY101) For All Patients With RANO-LGG Evaluable Lesions (n=76) Day One Biopharmaceuticals Dec 22, 2022 data cutoff. Percents may not add to 100% due to rounding. #PD for RANO-LGG was not used to determine treatment discontinuation; patients could continue treatment if
Slide 15: Duration Of Therapy For Patients With RANO-HGG Evaluable Lesions
Duration Of Tovorafenib (DAY101) Therapy For All Patients With RANO-HGG Evaluable Lesions (n=69) Day One Biopharmaceuticals 11/17 patients with stable disease <12 months remain on treatment as of data cutoff Partial response Complete response Progressive disease Discontinuation due to AE Death Ongoi
Slide 16: Duration Of Therapy RANO-HGG & RANO-LGG
Duration Of Tovorafenib (DAY101) Therapy For All Patients With RANO-HGG & RANO-LGG Evaluable Lesions Day One Biopharmaceuticals RANO-HGG (n=69) RANO-LGG (n=76) * Analysis for median time to response and median duration of response only included confirmed responses. BOR is shown; circles indicate sta
Slide 17: Unconfirmed PR Patients Continue On Treatment With Deepening Of Response
All RANO-LGG Unconfirmed PR Patients Continue On Treatment With Demonstrable Deepening Of Response (n=8) Day One Biopharmaceuticals Responses for Patients with Unconfirmed Partial Response by RANO-LGG Spider plot for SPPD – baseline and after treatment (RANO-LGG by IRC) – unconfirmed PR patients EOT
Slide 18: Patients With Best Response Of PD By RANO-LGG Have Tumor Stabilization
Nearly Half Of Patients With Best Response Of PD By RANO-LGG Have Tumor Stabilization And Response With Continued Treatment (n=11) Day One Biopharmaceuticals 5/11 patients with best response of PD by RANO-LGG remain on treatment as of May 23, 2023 Ongoing treatment Discontinued treatment Individual
Slide 19: Tovorafenib Safety Data (n=136)
Tovorafenib (DAY101) Safety Data (n=136) Day One Biopharmaceuticals Preferred term, n (%) Treatment-emergent AEs Treatment-related AEs Any grade Grade ≥3 Any grade Grade ≥3 Any AE 136 (100) 68 (50) 133 (98) 47 (35) Hair color changes 96 (71) - 96 (71) - Fatigue 68 (50) 4 (3) 54 (40) 4 (3) Vomiting 5
Slide 20: Incidence And Prevalence Of BRAF-Altered pLGG In The U.S.
Incidence And Prevalence Of BRAF-Altered pLGG In The U.S. Day One Biopharmaceuticals ~26,000 Estimated Prevalence 2020 Estimated Incidence Under 25 US Population1 ~105,000,000 Rate of CNS Tumors (0.00521%)2 ~5,500 Gliomas (63%)2 ~3,500 Low Grade (77%)2 ~2,600 Has Received Drug Tx (58%)2 ~1,500 BRAF
Slide 21: Key Takeaways From FIREFLY-1 Data And Next Steps
Key Takeaways From FIREFLY-1 Data And Next Steps Day One Biopharmaceuticals Dec 22, 2022 data cutoff. *Pending adjudication. # Analysis for median time to response only included confirmed responses. Next Steps Expected completion of rolling NDA by October 2023 following submission of an amended clin
Slide 22: FIREFLY-2/LOGGIC Pivotal Phase Trial in Frontline pLGG
FIREFLY-2/LOGGIC Pivotal Phase 3 Trial of Tovorafenib (DAY101) in Frontline pLGG Day One Biopharmaceuticals Confidential Information
Slide 23: FIREFLY-2/LOGGIC Pivotal Phase 3 Trial In Frontline pLGG
FIREFLY-2/LOGGIC Pivotal Phase 3 Trial Of Tovorafenib (DAY101) In Frontline pLGG Day One Biopharmaceuticals 1:1 Randomization Tovorafenib, 420mg/m2 QW (not to exceed 600 mg) Investigator's choice of vincristine/carboplatin* or vinblastine Long-term follow-up (48 months) Stratified by Location of tum
Slide 24: FIRELIGHT-1 Phase 1b/2 Trials
FIRELIGHT-1 Phase 1b/2 Trials Evaluating Tovorafenib (DAY101) as a Monotherapy and as a Combination with Pimasertib Day One Biopharmaceuticals Confidential Information
Slide 25: Phase Study Of Monotherapy Tovorafenib In Solid Tumors (FIRELIGHT-1)
Phase 2 Study Of Monotherapy Tovorafenib (DAY101) In Solid Tumors (FIRELIGHT-1) Day One Biopharmaceuticals Patients with a known BRAF or CRAF/RAF1 fusion, or CRAF/RAF1 amplification Melanoma cohort “Tissue agnostic” cohort Study Drug Administration ≥ 18 years at 600 mg PO QW 12 to <18 years at 420mg
Slide 26: Activity of Tovorafenib In SNX8:BRAF Fusion Spindle Cell Sarcoma
Activity of Tovorafenib (DAY101) In SNX8:BRAF Fusion Spindle Cell Sarcoma Day One Biopharmaceuticals Months -30 -24 -18 -12 -6 0 6 Diagnosis BRAF fusion (FISH) CR PD CR Gemcitabine, docetaxel Proton radiotherapy SNX8-BRAF fusion Targeted Therapy Subtotal resection Ifosfamide, doxorubicin, dexrazoxan
Slide 27: Pimasertib MEK1/2 Inhibitor
Pimasertib MEK1/2 Inhibitor Day One Biopharmaceuticals
Slide 28: Pimasertib: Investigational Allosteric MEK1/2 Inhibitor
Pimasertib: Investigational Allosteric MEK1/2 Inhibitor With Demonstrated Activity In MAPK-Driven Solid Tumors Day One Biopharmaceuticals Pimasertib is an investigational orally-bioavailable, selective, non-competitive MEK1/2 inhibitor in-licensed from Merck KGaA in February 2021 Extensive non-clini
Slide 29: Vertical MAPK Pathway Inhibition With Tovorafenib And Pimasertib
Vertical MAPK Pathway Inhibition With Tovorafenib (DAY101) And Pimasertib May Unlock Potential Synergy For Adult Solid Tumors Day One Biopharmaceuticals Pan-RAFi + MEKi is synergistic in BRAF fusion melanoma PDX model ex vivo (internal data) Sensitivity of KRAS Q61 mutant cells to pimasertib is enha
Slide 30: Tovorafenib / Pimasertib Combination In Solid Tumors (FIRELIGHT-1)
Tovorafenib (DAY101) / Pimasertib Combination To Be Evaluated In Solid Tumors (FIRELIGHT-1) Day One Biopharmaceuticals Pre-identified patients with advanced solid tumors and available clinical molecular profiling information. Phase 1b Tumors with MAPK pathway alterations *Additional biomarker-select
Slide 31: Summary
Summary Day One Biopharmaceuticals
Slide 32: Financial Summary: DAWN
Financial Summary: DAWN Day One Biopharmaceuticals $ Millions Six Months Ended 6/30/23 Six Months Ended 6/30/22 R&D Expense $60.0 $37.6 G&A Expense $35.1 $26.9 Net Loss $88.3 $64.3 Projected cash runway into 2026 FIREFLY-1: Pivotal Phase 2 clinical trial of tovorafenib (DAY101) Initiated rolling NDA
Slide 33: Next Steps
Next Steps Day One Biopharmaceuticals FIREFLY-1 Initiated rolling NDA in May 2023 New clinical data presented in June 2023 Expected completion of rolling NDA by October 2023 following submission of an amended clinical study report1 FIREFLY-2 Advance tovorafenib as a frontline therapy for patients wi
Slide 34: Appendix
Appendix
Slide 35: Progress Of FIREFLY-1 Program
Progress Of FIREFLY-1 Program: Monotherapy Tovorafenib In Relapsed pLGG Day One Biopharmaceuticals First Patient Dosed in FIREFLY-1 Trial (May 2021) Pivotal Cohort Enrollment Complete in FIREFLY-1 Trial (May 2022) Interim Analysis Data from FIREFLY-1 Trial (Jun 2022) Topline Data from FIREFLY-1 Tria
Slide 36: Case Study: KIAA1549-BRAF Fusion Optic Pathway Glioma
Diagnostic biopsy Months A 7-years-old female child with an optic pathway glioma, with very poor vision, entropion, folliculitis, eczema, mouth ulceration and xerosis Case Study: Activity Of Tovorafenib (DAY101) In KIAA1549-BRAF Fusion Optic Pathway Glioma Day One Biopharmaceuticals PR 1L: Vincristi
Slide 37: Case Study: KIAA1549-BRAF Fusion Posterior Fossa Pilocytic Astrocytoma
Months An 8-years-old female child with a posterior fossa pilocytic astrocytoma, eczema, nausea and constipation Case Study: Activity Of Tovorafenib (DAY101) In KIAA1549-BRAF Fusion Posterior Fossa Pilocytic Astrocytoma Day One Biopharmaceuticals Suboccipital craniotomies 2L: Carboplatin/vincristine
Slide 38: Case Study: BRAF V600E Mutation Deep Midline Astrocytoma
Months A 9-year-old female child with deep midline BRAF V600E-mutant astrocytoma with precocious puberty -60 Case Study: Activity Of Tovorafenib (DAY101) In BRAF V600E Mutation Deep Midline Astrocytoma Day One Biopharmaceuticals PR -48 -36 -24 -12 0 12 2L: Dabrafenib Best response PR 3L: Tovorafenib
Slide 39: Case Study: KIAA1549-BRAF Fusion Optic Pathway Glioma Tumor Kinetics
Case Study: Activity Of Tovorafenib (DAY101) In KIAA1549-BRAF Fusion Optic Pathway Glioma Day One Biopharmaceuticals Tumor kinetics Dec 22, 2022, data cut-off. AEs, adverse events; C, contrast; CPK, creatine phosphokinase; G, grade; HGG, high-grade glioma; LGG, low-grade glioma; logMAR, Logarithm of
Slide 40: Collaboration between Day One and the LOGGIC consortium
Collaboration between Day One and the LOGGIC consortium, internationally recognized experts in pLGG research Coupled with the LOGGIC-CORE molecular diagnostic program Worked jointly on the study design and discussions with the U.S. and EU regulatory authorities FIREFLY-2/LOGGIC: Pivotal Phase 3 Stud
Slide 41: Results From Independent Radiology Review Of PNOC014
Results From Independent Radiology Review Of PNOC014 Day One Biopharmaceuticals RAPNO: Response assessment for pediatric neuro-oncology (exploratory) RANO-HGG: Response assessment for neuro-oncology-high grade glioma Volumetric image analysis (exploratory) Best response from baseline Date of data cu
Slide 42: Rapid, Deep And Durable Responses In PNOC014
Multiple Rapid, Deep And Durable Responses Observed Following Initiation Of Tovorafenib (DAY101) Treatment Of pLGG Patients In PNOC014 Day One Biopharmaceuticals Date of data cutoff: 02 JAN 2020 Adapted from Wright K et. al. Neuro Oncology Abstract CTNI-19. 2020 Fangusaro J et al. Lancet Oncol 2019
Slide 43: Drug-related Adverse Events For Tovorafenib in PNOC014
Drug-related Adverse Events Observed for Tovorafenib (DAY101) in PNOC014 Showed Favorable Safety and Tolerability Profile in pLGG Day One Biopharmaceuticals Toxicities Grade 1-2 Grade 3 Grade 4 Anemia 6 (67%) Hypophosphatemia 4 (44%) Fatigue 5 (55%) Rash 8 (89%) Achromotrichia 7 (78%) Pruritis 6 (67
Slide 44: Tovorafenib Activity In BRAF Fusion Melanoma (Patient 1)
Preliminary Clinical Activity Of Tovorafenib (DAY101) Monotherapy In BRAF Fusion Melanoma Day One Biopharmaceuticals Parameter Description/outcome Stage at diagnosis III EGOC status 0 Prior therapies Multiple lymphadenectomies and skin lesion excision surgery Pembrolizumab (11 weeks): Best response:
Slide 45: Tovorafenib Activity In BRAF Fusion Melanoma (Patient 2)
Preliminary Clinical Activity Of Tovorafenib (DAY101) Monotherapy In BRAF Fusion Melanoma Day One Biopharmaceuticals Parameter Description/outcome Stage at diagnosis Unknown EGOC status 1 Prior therapies Radiation Nivolumab (12 mo, adjuvant setting): No best response, disease resected Nivolumab + ip
Slide 46: Tovorafenib Activity In BRAF Fusion Melanoma (Patient 3)
Preliminary Clinical Activity Of Tovorafenib (DAY101) Monotherapy In BRAF Fusion Melanoma Day One Biopharmaceuticals Parameter Description/outcome Stage at diagnosis II EGOC status 0 Prior therapies Radiation Pembrolizumab (2 mo): Best response: SD Tovorafenib treatment to date in FL-1 102a (melanom
Day One Biopharmaceuticals — Q2 2023 Earnings Presentation on 6ix